UK Markets close in 5 hrs 5 mins

GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,467.00-7.40 (-0.50%)
As of 11:10AM BST. Market open.
Sign in to post a message.
  • E
    BRUSSELS, Sept 18 (Reuters) - The European Union has agreed an advance purchase agreement with Sanofi and GlaxoSmithKline to buy the companies' potential COVID-19 vaccine, according to a tweet from European Health Commissioner Stella Kyriakides.

    The agreement is the second such deal struck by the European Union. Kyriakides said she was hosting the signature of the contract.

    The deal, for all 27 EU countries, covers the purchase of 300 million doses.

    In return for the right to the doses, the European Commission will finance part of the upfront costs faced by vaccine producers. The vaccine doses themselves would be bought by EU countries. (Reporting by Philip Blenkinsop and Jan Strupczewski, editing by Marine Strauss)
  • S
    If your email program has trouble displaying this email, view as a webpage.

    US Food and Drug Administration
    FDA Approves First Drug to Treat Group of Rare Blood Disorders in Nearly 14 Years
    Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease. The new indication for Nucala is the first approval for HES patients in nearly 14 years.

    “Today’s approval marks the first time in over a decade that there is a new FDA-approved treatment option for patients with hypereosinophilic syndrome,” said Ann Farrell, M.D., director of the Division of Nonmalignant Hematology in the FDA’s Center for Drug Evaluation and Research. “FDA is committed to helping develop safe and effective treatment options for this group of rare and debilitating blood diseases and other rare conditions.”

    HES is a heterogeneous group of rare disorders associated with persistent eosinophilia (higher than normal levels of a type of disease-fighting white blood cell) with evidence of organ damage. Symptoms include skin rashes, itching, asthma, difficulty breathing, abdominal pain, vomiting, diarrhea, arthritis, muscle inflammation, congestive heart failure, deep venous thrombosis (blood clots in the veins) and anemia.

    Nucala was evaluated in a randomized, double-blind, multicenter, placebo-controlled trial in 108 patients with HES. In the study, patients were randomly assigned to receive Nucala or placebo by injection every four weeks. The trial compared the proportion of subjects who experienced a HES flare during the 32-week treatment period. A HES flare was defined as worsening of clinical signs and symptoms of HES or increasing eosinophils (disease-fighting white blood cells) on at least two occasions. The trial compared the proportions of patients with at least one flare over a 32-week treatment period, as well as the time to the first flare. Fewer patients in the Nucala treatment group (28%) had HES flares compared to patients in the placebo group (56%), with a 50% relative reduction. In addition, the time to the first HES flare was later, on average, for patients treated with Nucala vs. placebo.

    The most common side effects of Nucala in patients with HES include: upper respiratory tract infection and pain in extremities (such as the hands, legs and feet).

    Nucala should not be administered to patients with a history of hypersensitivity to mepolizumab or one of its ingredients.

    Herpes zoster (shingles) infections have occurred in patients receiving Nucala. Health care providers should consider vaccination if medically appropriate.

    For the treatment of HES, Nucala received orphan drug designation, which provides incentives to assist and encourage drug development for rare diseases. Additionally, the application was granted fast track designation and priority review.

    The FDA is granting the approval to GlaxoSmithKline of Research Triangle Park, North Carolina. Nucala is also FDA-approved for patients aged 6 years and older with severe asthma with an eosinophilic phenotype and for adult patients with eosinophilic granulomatosis with polyangiitis, a rare autoimmune condition that causes blood vessel inflammation.
  • K
    Honestly, GSK has known 5 years of steady revenue and earnings growth and the share price hasn't moved an inch.

    And although revenue is down slightly year to date, we can expect GSK as the largest vaccine maker partnering with sanofi, the third largest vaccin maker to play a big part in the development, production and distribution of a potential covid vaccine.

    It's not exactly been a top performer in my portfolio, but I'm adding, it looks really cheap atm.
  • C
    $45 soon!
  • J
    Honestly this is such a good pipeline and would be one of my fav stocks out of the 40 bios that I have, but I feel that this stock gets the best of the best possible news and it is still flat every day. I decided to sell because I worried about missed opportunity since other stocks seem to rise just with the smallest amount of speculation. I do plan to buy back in...will likely be the same price exited it at.
  • J
    John Tiscione
    A British pharmaceutical company called GlaxoSmithKline currently manufactures a flu vaccine, which includes shark squalene, which is a natural oil produced in the liver. It's known to create a strong response from the recipient's immune system.

    The company plans to produce A BILLION DOSES of a coronavirus vaccine, which would include shark squalene.

    An environmental group called Shark Allies, claims a quarter-of-a-million sharks would have to be killed to produce the necessary amount of squalene for one dose per person. If 2 doses are required -- which may well be the case -- we're talking half a million sharks that would be killed.

    Stefanie Brendl, who runs Shark Allies, says, "Harvesting something from a wild animal is never going to be sustainable, especially if it's a top predator that doesn't reproduce in huge numbers."

    Squalene is a coveted ingredient in cosmetics and machine oil. Estimates are that 3 million sharks are killed every year for squalene. BTW ... Orca whales prey on shark livers and can almost surgically remove them. Some shark livers weigh as much as 180 lbs.
  • K
    Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate Pre-clinical studies show promising...
    Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate Pre-clinical studies show promising...
  • T
    gsk will have its day soon my friends
  • B
    Vir and GSK start Phase 2/3 trial for experimental COVID-19 treatment
    Published: Aug. 31, 2020 at 8:50 a.m. ET
  • P
    Big money shorting GSK to buy shares cheap. Great dividend & vaccine stock. Big money shaking 🌳
  • M
    Mr. Buddah
    Nvta morgan 38 tgt, getting stronger as day drags on.

    U x i n, nkla come back. Most of next to weeks.
  • E
    Great research by Zacks:

    "Value investors will likely look at more than just these metrics, but the above data helps show that GlaxoSmithKline is likely undervalued currently. And when considering the strength of its earnings outlook, GSK sticks out at as one of the market's strongest value stocks".
  • S
    GSK sold Canada plant to a Taiwan company for $25 million whereas it's value is $400 million.
    They got free land from the city & transferred to a foreign country.
    This is a loss to the city of Mississauga and Canada
  • R
    When will $gsk break out of this trading range? I was hoping this last little rise would do it, but now we are back to waiting.
  • B
    GSK declares FDA advisory committee votes for positive advantage/chance profile for belantamab mafodotin for patients with relapsed/refractory numerous myeloma. Meanwhile, this company could deliver a substantial investment opportunity, especially with the Gold Rush well under way. Read here:
    Gold Stocks Are Hot, Gold Keeps Inching Higher In Price, Here Is Why?
  • M
    I'm newer so bare with me..
    when nvax is around 20.00 it gets US funding and triples overnight then runs to over 100.

    now companies like Pheizer and now GSK get funding and their stock kinda sits still..

    You guess as to why other companies don't explode like nvax when they get billions of dollars?
  • T
    The Abominable Snow Clown
    Snow Clown reiterates $45 by Halloween.
  • M
    Mr. Buddah
    So simple, offer 80.00 a share for nvta before mrk does.

    Buddah, own the best test patents hands down, 30 billion in covid revenues by 2030.

    Gsk board members, you need invitae.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more